Další formáty:
BibTeX
LaTeX
RIS
@article{1317134,
author = {Krajčovičová, Renáta and Hudeček, Robert and Ventruba, Pavel and Surgentová, Katarína},
article_location = {Larchmont},
article_number = {5},
doi = {http://dx.doi.org/10.1089/gyn.2014.0129},
keywords = {Asherman´s syndrome; menstrual cycle; hormonal therapy; hyaluronan},
language = {eng},
issn = {1042-4067},
journal = {Journal of gynecologic surgery},
title = {The Role of Hyaluronan in Asherman’s Syndrome Therapy},
volume = {31},
year = {2015}
}
TY - JOUR
ID - 1317134
AU - Krajčovičová, Renáta - Hudeček, Robert - Ventruba, Pavel - Surgentová, Katarína
PY - 2015
TI - The Role of Hyaluronan in Asherman’s Syndrome Therapy
JF - Journal of gynecologic surgery
VL - 31
IS - 5
SP - 250-254
EP - 250-254
PB - Mary Ann Liebert Inc.
SN - 10424067
KW - Asherman´s syndrome
KW - menstrual cycle
KW - hormonal therapy
KW - hyaluronan
N2 - Prospective clinical evaluation comparing the therapy of Asherman’s syndrome in patients treated using hysteroscopic (HSK) adhesiolysis with insertion of 100% hyaluronic acid (HA) to a patient cohort with an inserted intrauterine device (IUD) and a control cohort. Design: Primary outcome—treatment for menstrual cycle problems. Secondary outcome—attainment of pregnancy after spontaneous conception within 1 year after the ending of hormonal therapy. Materials and Methods: Sixty patients treated from 1997 to 2014 for Asherman’s syndrome (in Stage II and III). Cohort A: Insertion of 100% HA (20 patients). Cohort B: Insertion of an IUD (18 patients). Cohort C: Without insertion of antiadhesion agent (22 patients). Primary and secondary goals were evaluated for all patients after a 3-month hormonal therapy. Results: The normal menstrual cycle was restored in 12 out of 20 patients in cohort A (60.0%), in 10 out of 18 patients in cohort B (55.5%), and 8 out of 22 patients in control cohort C (36.3%). A spontaneous pregnancy within 1 year after the end of the treatment was achieved by 14 out of 18 patients (77.7%) in cohort A, by 6 out of 10 patients (60.0%) in cohort B, and by 6 out of 14 patients (42.8%) in cohort C. Ten patients (55.5%) gave birth in cohort A, 4 patients (40.0%) in cohort B, and 4 patients (28.5%) in cohort C. Given the small number of the included patients, there was no statistically significant difference identified in any of the followed cohorts through the completed statistical analysis. Conclusion: Intrauterine insertion of hyaluronan after the completed HSK adhesiolysis enabled the recovery of the normal menstrual cycle for 60.0% of the patients and improved the implantation rate (77.7%) and take home baby rate (55.5%), compared to the group of patients with insertion IUD and with the control group. ( J GYNECOL SURG 31:250)
ER -
KRAJČOVIČOVÁ, Renáta, Robert HUDEČEK, Pavel VENTRUBA a Katarína SURGENTOVÁ. The Role of Hyaluronan in Asherman’s Syndrome Therapy. \textit{Journal of gynecologic surgery}. Larchmont: Mary Ann Liebert Inc., 2015, roč.~31, č.~5, s.~250-254. ISSN~1042-4067. Dostupné z: https://dx.doi.org/10.1089/gyn.2014.0129.
|
